Evox Therapeutics
2016
FOUNDED
PRIVATE
STATUS
1-10
EMPLOYEES
Grant
LATEST DEAL TYPE
$1.98M
LATEST DEAL AMOUNT
10
INVESTORS
Description
Developer of exosome-based therapeutics designed to treat various severe diseases with limited options for patients and their families. The company's therapeutics use nucleic acid and protein delivery technology, enabling users to leverage proprietary targeting technology, manufacturing processes and purification methods.
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
- Oxford Science Park, Medawar Centre
- 2nd Floor East Building, Robert Robinson Avenue
- Oxford OX4 4HG
- England, United Kingdom
+44 01865 000000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Evox Therapeutics’s full profile, request a free trial.
Evox Therapeutics Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Grant | 22-Mar-2019 | $1.98M | 000.00 | Completed | Generating Revenue | |
| 3. Grant | 13-Nov-2018 | 00000 | 000.00 | Completed | Generating Revenue | |
| 2. Early Stage VC (Series B) | 03-Sep-2018 | $45.6M | $60.2M | 000.00 | Completed | Generating Revenue |
| 1. Seed Round | 10-May-2016 | $14.6M | $14.6M | 0000 | Completed | Clinical Trials - Phase 1 |
Evox Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|---|---|---|---|---|---|---|---|
| A Preferred | 000,000 | 00.000000 | 00 | 0000.0 | 0000.0 | 00 | 0000.0 | 00.000 |
| Ordinary | 000,000 | 00.000000 | 00 | 000.00 | 000.00 | 00 | 000.00 | 00.000 |
Evox Therapeutics Competitors (14)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Codiak | Venture Capital-Backed | Cambridge, MA | 00 | 00000 | 00000000 | |
| 000000 00000000000 | Venture Capital-Backed | Cambridge, MA | 0 | 0000 | 00000000000 | 0000 |
| 0000000 (000000000 | Venture Capital-Backed | Cambridge, MA | 00 | 0000 | 00000000000 | 0000 |
| 0000000 0000000000 | Venture Capital-Backed | New York, NY | 0 | 00000 | 0000000000 | 00000 |
| 00000000 | Venture Capital-Backed | Seattle, WA | 0000 | 00000000000 | 0000 |
Evox Therapeutics Investors (10)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| Innovate UK | Government | 000 0000 | 000000 0 | |||
| Duchenne UK | Other | 000 0000 | 000000 0 | |||
| Bill & Melinda Gates Foundation | Not-For-Profit Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Borealis Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Cowen Healthcare Investments | Venture Capital | Minority | 000 0000 | 000000 0 |
Evox Therapeutics Executive Team (4)
Evox Therapeutics Board Members (8)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Adam Stoten | Self | Board Member | 000 0000 | |
| Amrit Nagpal | Redmile Group | Board Member | 000 0000 | |
| Andrew McLean MD | Oxford Sciences Innovation | Board Member | 000 0000 | |
| Antonin de Fougerolles Ph.D | Evox Therapeutics | Chief Executive Officer & Board Member | 000 0000 | |
| Edwin Moses Ph.D | Self | Chairman | 000 0000 |